6533b85ffe1ef96bd12c1366

RESEARCH PRODUCT

Angiotensin converting enzyme has an inhibitory role in CGRP metabolism in human skin

Katharina SchmidtClaudia SommerStefan LeisMartin SchmelzHeidrun H. KrämerFrank Birklein

subject

AdultMalemedicine.medical_specialtyCaptoprilPhysiologyCalcitonin Gene-Related PeptideNeuropeptideAngiotensin-Converting Enzyme InhibitorsPeptidyl-Dipeptidase ACalcitonin gene-related peptideBiochemistryCellular and Molecular Neurosciencechemistry.chemical_compoundEndocrinologyInternal medicineRetrograde DegenerationLaser-Doppler FlowmetrymedicineHumansNeprilysinSkinintegumentary systembiologyChemistryCatabolismfungiPhosphoramidonGlycopeptidesAngiotensin-converting enzymeCaptoprilMetabolismrespiratory systemVasodilationEndocrinologybiology.proteinFemalemedicine.drug

description

The neutral endopeptidase (NEP) is important for calcitonin gene related peptide (CGRP) degradation, while the role of angiotensin converting enzyme (ACE) remains unclear. By using dermal microdialysis we explored the effect of phosphoramidon (NEP blocker), captopril (ACE blocker) and a mixture of both drugs on the intensity of electrically-induced CGRP-mediated neurogenic flare. The results reveal that phosphoramidon elevated flare intensity, but that this was not further increased by adding captopril. In contrast, neurogenic flare was decreased when the drug mixture was applied in compared to NEP only. Electrically released CGRP levels could be measured directly in perfusates containing phosphoramidon and the mixture. Again, CGRP levels were elevated in phosphoramidon treated sites, and significantly reduced upon adding captopril. These findings suggest that NEP and ACE do not have additive effects regarding neuropeptide degradation. In contrast, inhibition of ACE seems to augment CGRP catabolism.

yearjournalcountryeditionlanguage
2005-07-18Peptides
https://doi.org/10.1016/j.peptides.2005.08.007